These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Long-term antithrombotic treatment in patients with valve prostheses. Practical management and complications].
    Author: Delahaye JP, Milon H, Ffrench P, Philippe-Bert J, Malquarti V, Saradarian W.
    Journal: Ann Cardiol Angeiol (Paris); 1985 Apr 15; 34(4):205-11. PubMed ID: 3893303.
    Abstract:
    The cumulative annual risk of thrombo-embolic and haemorrhagic complications due to anticoagulants in patients with mechanical prostheses is in the order of 3 to 9 p. cent for mitral prostheses and mitral and aortic prostheses and 2 to 5 p. cent for aortic prostheses. Anticoagulant drugs should be chosen in terms of the type and the site of the implanted prosthesis and the coefficient of the thrombo-embolic and haemorrhagic risk of each subject. In patients with mechanical prostheses, the most effective prevention of the thrombo-embolic risk is ensured by the anti-vitamin K drugs associated with dipyridamole, with a low haemorrhagic risk if the treatment is correctly controlled. In patients with bioprostheses, the anticoagulant treatment (anti-vitamin K or anti-platelet drugs) should be maintained for three to six months after the operation; the anti-vitamin K drugs should not be prolonged indefinitely, except in patients at high risk of thrombo-embolism (atrial fibrillation with a very dilated left auricle, in particular). The management of a pregnant woman with a valve prosthesis and the problems of patients with prostheses undergoing extracardiac or dental operations or invasive investigations are still open to discussion.
    [Abstract] [Full Text] [Related] [New Search]